Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium | Zendy

Jonathan E. Rosenberg | Zendy; Charles J. Ryan | Zendy; Vivian Weinberg | Zendy; David C. Smith | Zendy; Maha Hussain | Zendy; Tomasz M. Beer | Zendy; Christopher W. Ryan | Zendy; Paul Mathew | Zendy; Lance C. Pagliaro | Zendy; Andrea Harzstark | Zendy; Jeremy Sharib | Zendy; Eric J. Small | Zendy

Open Access

Phase I Study of Ixabepilone, Mitoxantrone, and Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Therapy: A Study of the Department of Defense Prostate Cancer Clinical Trials Consortium

Author(s) -

Jonathan E. Rosenberg,

Charles J. Ryan,

Vivian Weinberg,

David C. Smith,

Maha Hussain,

Tomasz M. Beer,

Christopher W. Ryan,

Paul Mathew,

Lance C. Pagliaro,

Andrea Harzstark,

Jeremy Sharib,

Eric J. Small

Publication year - 2009

Publication title -

journal of clinical oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 10.482

H-Index - 548

eISSN - 1527-7755

pISSN - 0732-183X

DOI - 10.1200/jco.2008.19.8002

Subject(s) - medicine , ixabepilone , mitoxantrone , docetaxel , pegfilgrastim , prostate cancer , febrile neutropenia , neutropenia , prednisone , phases of clinical research , oncology , gastroenterology , chemotherapy , surgery , cancer , urology , metastatic breast cancer , breast cancer

Mitoxantrone plus prednisone and ixabepilone each have modest activity as second-line chemotherapy in docetaxel-refractory castration-resistant prostate cancer (CRPC) patients. Clinical noncrossresistance was previously observed.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research